

S7 Table. Systemic therapy in the oligoprogression group (n=122)

	No. (%)
Systemic regimen at the time of LART	
TKI	50 (41.0)
Immunotherapy	43 (35.2)
Cytotoxic CTx	27 (22.1)
Nth line systemic therapy	
1	35 (28.7)
2	44 (36.1)
3	25 (20.5)
4	13 (10.7)
≥ 5	5 (4.1)
Maintained the systemic regimen after LART	
Yes	82 (67.2)
No	40 (32.8)

CTx, chemotherapy; LART, local ablative radiotherapy; TKI, tyrosine kinase inhibitor.